P2Y14 Receptor Antagonists Containing A Biaryl Core

The technology discloses composition of compounds that fully antagonize the human P2Y14 receptor, with moderate affinity with insignificant antagonism of other P2Y receptors. Therefore, they are highly selective P2Y14 receptor antagonists. Even though there is no P2Y14 receptor modulators in clinical use currently, selective P2Y14 receptor antagonists are sought as potential therapeutic treatments for asthma, cystic fibrosis, inflammation and possibly diabetes and neurodegeneration.NIDDKE-028-2018-0Development of P2Y14 receptor antagonist for treatment of disorders, such as:Inflammationdiabetescystic fibrosisasthmaneurodegeneration3426Nov 20, 2020Friday, November 20, 202062/628,699PCT/US19/1742216/967,177USPCTUSNIDDKNIDDKNIDDKNIDDKNIDDKhttp://irp.nih.gov/pi/kenneth-jacobsonBettyTongBG 12A RM 3011D
12 SOUTH [e-mail] Office of Technology TransferAnti-Inflammatory (including Autoimmune)PulmonaryRM Catalog - reviewed and deemed appropriate for RM CatalogDiabetesResearch ToolTherapeutic (small molecule)PlatformIn vitro data availableInternal Medicine - Therapeutics: Anti-InflammatoryInternal Medicine - Therapeutics: PulmonaryInternal Medicine - Research Materials (appropriate for RM Catalog)DiabetesResearch ToolTherapeutic (small molecule)PlatformIn vitro data available2018-02-092019-02-112020-08-04doi: 10.1021/acs.jmedchem.8b00168doi: 10.1021/acs.jmedchem.0c00745doi: 10.1021/acs.jmedchem.8b00168doi: 10.1021/acs.jmedchem.0c00745Yu J,...

Source: NIH OTT Licensing Opportunities - November 20, 2020 Category: Research Authors: ott-admin Source Type: research